Is Royalty Pharma plc overvalued?

Royalty Pharma plc (RPRX) looks overvalued — trading about 61% above its fair value.

Overvalued

Price

$69.31

Fair value

$26.85

Current P/E

38.5

Normal P/E

14.9

Market cap

$30.86B

Dividend yield

1.3%

Return on equity

9.9%

Sector

Healthcare

Fair value compares RPRX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks